{
  "docId": "019de075-8d44-7401-b489-ee436db9a207",
  "docSlug": "66ec60e76d61a423395d466c32dc56fb",
  "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 72,
  "pageCount": 75,
  "prevPage": 71,
  "nextPage": 73,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The chart shows tumor volume over time (D20-D30), with the combination therapy (teal line) showing a flat growth curve compared to monotherapies and vehicle controls.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/72",
  "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207",
  "deckJsonHref": "/decks/019de075-8d44-7401-b489-ee436db9a207.json",
  "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-72",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.46,
        "x": 0.48,
        "y": 0.238
      },
      "kind": "chart",
      "text": "Tumour Volume (mean +/- SD) Data from Combination Ibrutinib Study",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e3c435f-c0be-433e-a567-fe244eb714c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "TMD8 DLBCL cells are sensitive to both MALT1 and ibrutinib in vitro. However, administration of ibrutinib or '565 (30 mg/kg BID) showed no activity in the TMD8 model in vivo when administered alone. Notably, significant synergistic efficacy was observed when '565 was combined with ibrutinib in the study. '565 was well tolerated with body weight maintained in both monotherapy and combination groups.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c660d7a9-a010-4277-b144-56de519a2584",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Synergistic efficacy of '565 in combination with ibrutinib",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e251709b-6e12-46d8-ba38-6099b58a60e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "'565 deepens response to ibrutinib in vivo",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e2c86a2-962d-4a7f-9481-658d44fb859c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}